Who is sponsoring NCT04743947?

NCT04743947 is sponsored by Heinrich-Heine University, Duesseldorf.

What drugs are being tested in NCT04743947?

Interventions in NCT04743947: No intervention; observational study.

What condition does NCT04743947 study?

NCT04743947 studies Chronic Kidney Disease Stage 5 on Dialysis, Chronic Kidney Disease Stage 5 With Transplant, Vaccine Response Impaired.

Is NCT04743947 still recruiting?

NCT04743947 is currently status unknown. Last updated 10 January 2022.

Last reviewed 2022-01-10 · How we verify

NCT04743947

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Vaccination Against COVID-19 in Chronic Kidney Disease

Status unknown Last updated 10 January 2022

What this trial tests

trial testing No intervention; observational study in Chronic Kidney Disease Stage 5 on Dialysis in 400 participants. Status unknown.

Timeline

21 December 2020

Primary endpoint
31 December 2024

31 December 2025

Quick facts

Lead sponsor	Heinrich-Heine University, Duesseldorf
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	400
Start date	21 December 2020
Primary completion	31 December 2024
Estimated completion	31 December 2025
Sites	5 locations across Germany

Drugs / interventions tested

No intervention; observational study

Conditions studied

Chronic Kidney Disease Stage 5 on Dialysis — all drugs for Chronic Kidney Disease Stage 5 on Dialysis →
Chronic Kidney Disease Stage 5 With Transplant — all drugs for Chronic Kidney Disease Stage 5 With Transplant →
Vaccine Response Impaired — all drugs for Vaccine Response Impaired →

Sponsor

Heinrich-Heine University, Duesseldorf

Who can join

18 and older, any sex, with Chronic Kidney Disease Stage 5 on Dialysis or Chronic Kidney Disease Stage 5 With Transplant. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective, multi-center, observational study that will enroll patients receiving dialysis (hemodialysis or peritoneal dialysis) or patients with kidney transplantation who will be vaccinated against COVID-19.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Intensity of mycophenolate mofetil treatment is associated with an impaired immune response to SARS-CoV-2 vaccination in kidney transplant recipients.
Kantauskaite M, Müller L, Kolb T, Fischer S, et al · · 2022 · cited 112× · PMID 34551181 · DOI 10.1111/ajt.16851
Impaired Immune Response to SARS-CoV-2 Vaccination in Dialysis Patients and in Kidney Transplant Recipients.
Kolb T, Fischer S, Müller L, Lübke N, et al · · 2021 · cited 42× · PMID 35373105 · DOI 10.34067/kid.0003512021
Immune response to third SARS-CoV-2 vaccination in seronegative kidney transplant recipients: Possible improvement by mycophenolate mofetil reduction.
Kantauskaite M, Müller L, Hillebrandt J, Lamberti J, et al · · 2022 · cited 18× · PMID 35997031 · DOI 10.1111/ctr.14790
SARS-CoV-2 vaccination in patients receiving kidney replacement therapies: where are we now with the protective immune response?
Toapanta N, Bestard O, Soler MJ. · · 2021 · cited 5× · PMID 34289072 · DOI 10.1093/ndt/gfab227
Comparison of immune responses to SARS-CoV-2 spike following Omicron infection or Omicron BA.4/5 vaccination in kidney transplant recipients.
Tometten I, Brandt T, Schlotz M, Stumpf R, et al · · 2024 · cited 1× · PMID 39877366 · DOI 10.3389/fimmu.2024.1476294
Immune response to third SARS-CoV-2 vaccination in seronegative kidney transplant recipients: possible improvement by mycophenolate mofetil reduction
Kantauskaite M, Müller L, Hillebrandt J, Lamberti J, et al · · 2022 · DOI 10.1101/2022.01.18.22269420

Verify or expand the search:

Other Heinrich-Heine University, Duesseldorf trials

Trials by the same sponsor.

NCT04993508 — Randomized Prospective Multi Center Cohort Study for Primary Diagnosis of Clinically Significant Prostate Cancer With Co · NA · not yet recruiting
NCT07385482 — Chronic and Acute Cardiovascular Diseases in Elderly Intensive Care Patients · not yet recruiting
NCT07455097 — COMBINED PSMA-PET/CT AND MRI STAGING IN INTERMEDIATE AND HIGH-RISK PATIENTS PROSTATA-CANCER (COMBINE-P) · active not recruiting
NCT07254663 — GEL & MEDication Dysphagia · recruiting
NCT06313944 — German Registry of Alzheimer's Disease Treated With Transcranial Pulse Stimulation · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04743947 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Heinrich-Heine University, Duesseldorf
Last refreshed: 10 January 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04743947.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing